Biochemical Mechanism of Modulation of Human P-glycoprotein by Stemofoline

Abstract

The resistance to chemotherapeutic drugs by cancer cells is considered to be one of the major obstacles for success in the treatment of cancer. A major mechanism underlying this multidrug resistance is the overexpression of P-glycoprotein (P-gp), resulting in insufficient drug delivery to the tumor sites. A previous study has shown that stemofoline, an alkaloid isolated from Stemona burkillii, could enhance the sensitivity of chemotherapeutics in a synergistic fashion. In the present study, we have focused on the effect of stemofoline on the modulation of P-gp function in a multidrug resistant human cervical carcinoma cell line (KB-V1). The effects of stemofoline on a radiolabeled drug, [³H]-vinblastine, and fluorescent P-gp substrates, rhodamine 123 and calcein-AM accumulation or retention were investigated to confirm this finding. Stemofoline could increase the accumulation or retention of radiolabeled drugs or fluorescent P-gp substrates in a dose-dependent manner. For additional studies on drug-P-gp binding, P-gp ATPase activity was stimulated by stemofoline in a concentration-dependent manner. More evidence was offered that stemofoline inhibits the effect on photoaffinity labeling of P-gp with [¹²⁵I]-iodoarylazidoprazosin in a concentration-dependent manner. These data indicate that stemofoline may interact directly with P-gp and inhibit P-gp activity, whereas stemofoline has no effect on P-gp expression. Taken together, the results exhibit that stemofoline possesses an effective MDR modulator, and may be used in combination with conventional chemotherapeutic drugs to reverse MDR in cancer cells.

P-glycoprotein - stemofoline - multidrug resistance - Stemona burkillii - Stemonaceae - KB-V1

References

• 1 Ramachandra M, Ambudkar S V, Chen D, Hrycyna C A, Dey S, Gottesman M M, Pastan I. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.  Biochemistry. 1998;  37 5010-5019
• 2 Sharom F J. The P-glycoprotein efflux pump: how does it transport drugs?.  J Membr Biol. 1997;  160 161-175
• 3 Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer.  Biochim Biophys Acta. 1996;  1288 F37-F54
• 4 Sharom F J, Liu R, Romsicki Y, Lu P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transport from spectroscopic studies.  Biochim Biophys Acta. 1999;  1461 327-345
• 5 Ambudkar S V, Kim I, Sauna Z E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).  Eur J Pharm Sci. 2006;  27 392-400
• 6 Sauna Z E, Ambudkar S V. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein.  J Biol Chem. 2001;  276 11653-11661
• 7 Hrycyna C A, Ramachandra M, Germann U A, Cheng P W, Pastan I, Gottesman M M. Both ATP sites of human P-glycoprotein are essential but not symmetric.  Biochemistry. 1999;  38 13887-13899
• 8 Litman T, Druley T E, Stein W D, Bates S E. From MDR to MXR: new understanding of multidrug resistance system, their properties and clinical significance.  Cell Mol Life Sci. 2001;  58 931-959
• 9 Chanmahasathien W, Ampasavate C, Greger H, Limtrakul P. Stemona alkaloids, from traditional Thai medicine, increase chemosensitivity via P-glycoprotein-mediated multidrug resistance.  Phytomedicine. 2011;  18 199-204
• 10 Greger H. Structure relationships, distribution and biological activities of Stemona alkaloids.  Planta Med. 2006;  72 99-113
• 11 Plouzek C A, Ciolino H P, Clarke R, Yeh G C. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract.  Eur J Cancer. 1999;  35 1541-1545
• 12 Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols.  Biochim Biophys Acta. 2002;  1542 149-159
• 13 Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.  Anal Biochem. 1976;  72 248-254
• 14 Sauna Z E, Muller M, Peng X, Ambudkar S V. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1).  Biochemistry. 2002;  41 13989-14000
• 15 Shukla S, Robey R W, Bates S E, Ambudkar S V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosone kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.  Drug Metab Dispos. 2009;  37 359-365
• 16 Ambudkar S V. Drug stimulatable ATPase activity in crude membranes of human MDR1 transfected mammalian cells.  Methods Enzymol. 1998;  292 504-514
• 17 Maki N, Hafkemeyer P, Dey S. Allosteric modulation of human P-gp.  J Biol Chem. 2003;  278 18132-18139
• 18 Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer.  FEBS Lett. 2006;  580 2903-2909
• 19 Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin.  J Chemother. 2005;  17 86-95
• 20 Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar S V, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder.  Biochem Pharmacol. 2004;  68 2043-2052
• 21 Anuchapreeda S, Ambudkar S V, Leechanachai P, Limtrakul P. Modulation of P-glycoprotein expression and function by curcumin in multidrug resistant human KB Cells.  Biochem Pharmacol. 2002;  64 573-582